Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07532603 · ClinicalTrials.gov registry record · Phase 2
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
A Phase 2 study, sponsored by Priovant Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 342
- Enrollment target
NCT07532603 is a Phase 2 study that is actively recruiting participants, run by Priovant Therapeutics. The registered enrollment target is 342 participants.
The verdict
NCT07532603, a Phase 2 study, is actively recruiting participants, sponsored by Priovant Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 342 participants
- Enrollment target
Study Summary
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris
Interventions
- DRUG Placebo
- DRUG Oral Brepocitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 2026-03-19 |
| Est. Completion | 2029-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07532603
The ClinicalTrials.gov registry entry for NCT07532603 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 342 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Priovant Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07532603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07532603 about?
NCT07532603 is a clinical study titled "A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris". This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris
What is the current status of trial NCT07532603?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 342 participants. The study started on 2026-03-19. Estimated completion is 2029-07-31.
What interventions are being tested in trial NCT07532603?
The interventions under investigation include: Placebo (DRUG), Oral Brepocitinib (DRUG).
Who is sponsoring clinical trial NCT07532603?
This trial is sponsored by Priovant Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.